Penn Medicine Provider
Gynecologic Oncology
Stephanie Jean, MD
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center West Chester
Make an appointmentCall 800-789-7366

About me

  • Assistant Professor of Clinical Obstetrics and Gynecology

Education and training

  • Medical School: State University of New York at Stony Brook
  • Residency: Hospital of the University of Pennsylvania
  • Fellowship: Hospital of the University of Pennsylvania

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Chester County Hospital: Has privileges to treat patients in the hospital.
Dr. Jean is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Nacarelli T, Fukumoto T, Zundell JA, Fatkhutdinov N, Jean S, Cadungog MG, Borowsky ME, Zhang R NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer. , Cancer Res, 80(4):890-900: 2020

Karakashev S, Fukumoto T, Zhao B, Lin J, Wu S, Fatkhutdinov N, Park PH, Semenova G, Jean S, Cadungog MG, Borowsky ME, Kossenkov AV, Liu Q, Zhang R EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition. , Cancer Cell, 37(2):157-167.e6: 2020

Zhao B, Lin J, Rong L, Wu S, Deng Z, Fatkhutdinov N, Zundell J, Fukumoto T, Liu Q, Kossenkov A, Jean S, Cadungog MG, Borowsky ME, Drapkin R, Lieberman PM, Abate-Shen CT, Zhang R ARID1A promotes genomic stability through protecting telomere cohesion. , Nat Commun, 10(1):4067: 2019

Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, Liu P, Kossenkov AV, Showe LC, Jean S, Zhang L, Zhang R N6-methylation of adenosine (m6A) of FZD10 mRNA contributes to PARP inhibitor resistance. , Cancer Res, 79(11):2812-2820: 2019

Singha B, Harper SL, Goldman AR, Bitler BG, Aird KM, Borowsky ME, Cadungog MG, Liu Q, Zhang R, Jean S, Drapkin R, Speicher DW CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. , Sci Rep, 8(1):14725: 2018

Fukumoto T, Park P, Wu S, Fatkhutdinov N, Karakashev S, Nacarelli T, Kossenkov AV, Speicher DW, Jean S, Zhang L, Wang T, Shih I, Conejo-Garcia JR, Bitler BG, Zhang R Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. , Cell Rep, 22(13):3393-3400: 2018

George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. , JCI Insight, 2(1):e89760: 2017

Jean S, Li J, Katsaros D, Wubbenhorst B, Maxwell KN, Fishbein L, Mclane MW, Benedetto C, Canuto EM, Mitra N, Zhang L, Nathanson KL, Tanyi, JL Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. , Oncotarget, 7(30):48577-48585: 2016

Jean S, Li J, Wubbenhorst B, Maxwell KN, Fishbein L, Mclane MW, Mitra N, Zhang L, Nathanson KL, Tanyi, JL Paclitaxel is necessary for improved survival in epithelial ovarian cancers with somatic homologous recombination gene mutations. Abstract presented, , American Association for Cancer Research Annual Meeting, Washington, DC: 2015

Jean S, Marsh EB and Chu CS Gynecology. , The Surgical Review: An Integrated Basic and Clinical Science Study Guide, 4th Edition, Chapter 28: 2015